ACAD short interest
Acadia Pharmaceuticals Inc. · Healthcare · Biotechnology · settlement date 2026-09-30
| Shares short | 8,275,918 |
|---|---|
| Change vs prior report | -1,391,054 (-14.4%) |
| Change over six months | -22.2% |
| Days to cover | 2.93 (sector: 3.78) |
| Average daily volume | 2,828,484 |
| Rank in Healthcare | #636 of 922 by days to cover |
ACAD short interest, last 12 months
| Settlement | Shares short | Change | Days to cover | Avg daily volume |
|---|---|---|---|---|
| 2026-09-30 | 8,275,918 | -14.4% | 2.93 | 2,828,484 |
| 2026-09-15 | 9,666,972 | -0.8% | 7.22 | 1,338,393 |
| 2026-08-31 | 9,739,720 | +2.8% | 6.93 | 1,404,719 |
| 2026-08-14 | 9,478,912 | -12.3% | 4.54 | 2,090,088 |
| 2026-07-31 | 10,812,093 | -2.0% | 7.96 | 1,358,749 |
| 2026-07-15 | 11,029,444 | +0.7% | 7.61 | 1,448,908 |
| 2026-06-30 | 10,951,125 | -7.3% | 4.75 | 2,307,777 |
| 2026-06-15 | 11,812,790 | +0.5% | 11.28 | 1,047,620 |
| 2026-05-29 | 11,754,100 | +2.9% | 8.08 | 1,454,891 |
| 2026-05-15 | 11,424,605 | +2.4% | 5.87 | 1,946,766 |
| 2026-04-30 | 11,156,379 | +1.6% | 5.89 | 1,894,956 |
| 2026-04-15 | 10,981,279 | +3.2% | 7.39 | 1,485,801 |
| 2026-03-31 | 10,638,508 | +23.4% | 4.93 | 2,158,686 |
| 2026-03-13 | 8,624,024 | -9.1% | 4.97 | 1,734,865 |
| 2026-02-27 | 9,490,106 | +6.6% | 4.96 | 1,914,400 |
| 2026-02-13 | 8,902,281 | -4.4% | 6.34 | 1,403,357 |
| 2026-01-30 | 9,313,368 | +11.3% | 7.24 | 1,286,570 |
| 2026-01-15 | 8,368,596 | -0.5% | 6.85 | 1,221,254 |
| 2025-12-31 | 8,414,309 | -3.1% | 6.55 | 1,283,730 |
| 2025-12-15 | 8,681,267 | -2.6% | 5.63 | 1,541,868 |
| 2025-11-28 | 8,911,463 | -5.7% | 6.67 | 1,336,272 |
| 2025-11-14 | 9,453,950 | +11.0% | 5.27 | 1,795,206 |
| 2025-10-31 | 8,513,644 | -2.7% | 4.97 | 1,714,407 |
| 2025-10-15 | 8,753,033 | -7.0% | 4.03 | 2,170,142 |
| 2025-09-30 | 9,411,032 | +17.9% | 3.51 | 2,683,307 |
import finzdata as yf
yf.Ticker("ACAD").short_interest # every report since 2017
yf.Client().short_interest(["ACAD"], start="2018-01-01")Healthcare short interest · ACAD price history · Who owns ACAD · All short interest